Previous close | 6.51 |
Open | 6.55 |
Bid | 6.34 x 500 |
Ask | 6.40 x 2000 |
Day's range | 6.38 - 6.72 |
52-week range | 3.16 - 10.13 |
Volume | |
Avg. volume | 5,533,820 |
Market cap | 1.487B |
Beta (5Y monthly) | 0.82 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.30 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 13.65 |
While Ardelyx, Inc. ( NASDAQ:ARDX ) shareholders are probably generally happy, the stock hasn't had particularly good...
Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 2, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2024. To part
WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on March 25, 2024, the compensation committee of the company’s board of directors granted a non-qualified stock option award to purchase 205,000 shares of its common stock and a restricted stock unit award for 160,000 shares in